Review of Ophthalmology April 2012 : covtip 1
LUMIGAN 0.01% preferred-status coverage ® Indication: LUMIGAN ® 0.01% and 0.03% is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Important Safety Information Warnings and Precautions LUMIGAN ® causes changes to pigmented tissues, mostly increased pigmentation of the iris, eyelid, and eyelashes as long as LUMIGAN ® is administered. Iris color change may not be noticeable for several months to years. After discontinuation of bimatoprost, iris pigmentation is likely to be permanent, while eyelid and eyelash changes have been reported to be reversible in some patients. Patients should be informed of the possibility of increased pigmentation. The long-term effects of increased pigmentation are not known. LUMIGAN ® should be used with caution in patients with active intraocular inflammation (eg, uveitis) because the inflammation may be exacerbated. Macular edema, including cystoid macular edema, has been reported ® LUMIGAN ® should be with LUMIGAN. used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema. Please see additional Important Safety Information on reverse side and brief Prescribing Information on page 5 inside this journal. Preferred Tier-2, and Approved Coverage: Preferred, Commercial Commer and Medicare Part D Lives 1,* 74 % LUMIGAN 0.01% ® 66 % 0 25 (travoprost ophthalmic solution) 0.004% Travatan Z ® 50 75 100 Percentage of 197,094,935 Lives Covered as of January 3, 2012 * With and without step-edits, and includes prior authorizations.
Using a screen reader? Click Here